TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer

卡波扎尼布 癌症研究 癌症 腺癌 胶质瘤 U87型 肺癌 耐受性 病理 医学 肿瘤科 内科学 不利影响
作者
Karen K. Briggs,K. Cottrell,A. Tsai,M. Zhang,M. Tonini,S. Yoda,Steven Lombardo,TSUNG‐HAN TENG,C. Davis,D. Whittington,H. DiBenedetto,A. Huang,J. Maxwell
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:174: S84-S84 被引量:5
标识
DOI:10.1016/s0959-8049(22)01021-8
摘要

TNG908 is a clinical stage MTA-cooperative PRMT5 inhibitor that leverages the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion. TNG908 was discovered using structure-based design following an initial high-throughput screening campaign. TNG908 is 15X selective for MTAPnull cell lines over isogenic MTAPWT cell lines and has marked selectivity for MTAP-deleted cancer cell lines independent of lineage in a large, diverse cell line panel. Oral administration of TNG908 drives dose-dependent, MTAPnull-selective antitumor activity in xenograft models, including durable tumor regressions in models representing glioblastoma, non-small cell lung cancer (adenocarcinoma and squamous), mesothelioma, cholangiocarcinoma, urothelial carcinoma, and others. TNG908 is brain-penetrant as exposure in the cerebrospinal fluid (CSF) approximates free, unbound plasma exposure in non-human primate studies. These data combined with strong preclinical activity in glioblastoma models strongly position TNG908 as a potential treatment of MTAP-deleted glioblastoma or solid tumor CNS metastases. A Phase 1/2 clinical trial (NCT05275478) is currently enrolling to assess safety, tolerability, and efficacy in patients with advanced or metastatic MTAP-deleted solid tumors, including non-small cell lung cancer (adenocarcinoma and squamous), mesothelioma, cholangiocarcinoma, malignant peripheral nerve sheath tumor, or in a lineage-agnostic cohort. In summary, TNG908 is a clinical stage, potent, brain-penetrant PRMT5 inhibitor with excellent drug-like properties and strong preclinical activity in multiple xenograft models that has the potential for histology-agnostic clinical development in MTAP-deleted solid tumors. Conflict of interest: Ownership: All authors are full-time employees of Tango Therapeutics and have stock and/or stock options.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
江江发布了新的文献求助20
刚刚
喔喔完成签到,获得积分10
刚刚
1秒前
SYX完成签到 ,获得积分10
1秒前
Lbc发布了新的文献求助10
2秒前
水月发布了新的文献求助10
2秒前
2秒前
jjj完成签到,获得积分10
2秒前
爆米花的应助被111采纳,获得20
3秒前
华生完成签到,获得积分10
3秒前
3秒前
4秒前
拼搏翠安完成签到 ,获得积分10
4秒前
汉堡包的应助被SSSDEFEFGG采纳,获得10
4秒前
4秒前
打打的应助被balabala19采纳,获得10
4秒前
PP的应助被Icey采纳,获得30
5秒前
hyan完成签到 ,获得积分10
5秒前
5秒前
欢呼的巧蕊完成签到,获得积分10
6秒前
elvira发布了新的文献求助10
6秒前
6秒前
含糊的白曼完成签到 ,获得积分10
6秒前
高贵烧鹅发布了新的文献求助10
7秒前
liwen发布了新的文献求助10
8秒前
萝卜的应助被fung采纳,获得10
8秒前
林莹发布了新的文献求助50
8秒前
9秒前
科研通AI2S的应助被小六九采纳,获得10
9秒前
wang完成签到,获得积分10
10秒前
10秒前
顺利的惮发布了新的文献求助10
10秒前
key完成签到,获得积分10
10秒前
学术舔狗完成签到,获得积分20
11秒前
tomatoGG发布了新的文献求助10
11秒前
11秒前
0227Y发布了新的文献求助10
11秒前
zss关闭了zss的文献求助
11秒前
11秒前
汉堡包的应助被科研通管家采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8160526
求助须知:如何正确求助?哪些是违规求助? 9555475
关于积分的说明 21728510
捐赠科研通 7750342
什么是DOI,文献DOI怎么找? 3427395
关于科研通互助平台的介绍 2552448
邀请新用户注册赠送积分活动 2471795